Enjoy complimentary customisation on priority with our Enterprise License!
The head and neck cancer treatment market size is estimated to grow by USD 7.12 billion at a CAGR of 13.64% between 2023 and 2028. The growth of the market is driven by several factors, including the increasing incidence of head and neck cancers, the growing geriatric population, and the rising number of cancer-related initiatives. These elements collectively propel market expansion by highlighting the urgent need for effective treatments, addressing demographic shifts, and fostering research and awareness. The increasing incidence of head and neck cancers underscores the demand for advanced medical solutions. Simultaneously, the growing geriatric population, which is more susceptible to such conditions, amplifies the need for specialized healthcare. Additionally, the rising number of cancer-related initiatives promotes early detection, research, and comprehensive care, further driving market growth.
The growing geriatric population is significantly boosting the growth of the market. As people age, their immunity and self-healing abilities decline, making them more susceptible to chronic conditions like cancer. With the global rise in the elderly population, there is a corresponding increase in cancer prevalence, driving strong demand for diagnostic, assistance, maintenance, and treatment-related equipment. Despite the complexities of multimodality therapy for head and neck cancer, the increased rates of oral HPV infections and HPV-driven cancers have led to a higher incidence of oral SCC among older adults. In the UK, nearly two-thirds of mouth cancer cases are diagnosed in individuals over 55. Consequently, the growing geriatric population is amplifying the demand for early detection and treatment procedures for head and neck cancer worldwide, which is expected to drive market growth.
To learn more about this report, Request Free Sample
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Amgen Inc., AstraZeneca Plc, Ayala Pharmaceuticals Inc., Bristol Myers Squibb Co., Debiopharm International SA, Eli Lilly and Co., Incyte Corp., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the injectable segment will be significant during the forecast period. Injectable drugs are administered directly into the bloodstream, making them a suitable and convincing treatment option for patients. The injectable drugs segment includes different types of drugs, such as chemotherapy agents, targeted therapies, immunotherapy, and supportive care medications.
Get a glance at the market contribution of various segments Download PDF Sample
The injectable segment was valued at USD 4.26 billion in 2018. Cisplatin is one of the injectable drugs used in head and neck cancer treatment a chemotherapy agent that is commonly used in combination with other drugs to treat various types of cancers, including head and neck cancer. Further, the convenience and efficiency of injectable drugs permit the precise and controlled delivery of the medication, assuring maximum efficacy. In addition, the development of novel injectable formulations with improved pharmacokinetics and fewer side effects has expanded the demand for injectable drugs further in head and neck cancer treatment. Therefore, such factors are anticipated to expand the demand for injectable drugs and therapies for treating head and neck cancer treatment, which will drive the growth of the injectable segment of the market during the forecast period.
Immunotherapy refers to the use of substances, such as monoclonal antibodies, vaccines, and immune checkpoint inhibitors, to enhance the body's immune system and specifically target cancer cells. This approach has shown promising results in treating head and neck cancer patients, leading to its increasing adoption in clinical practice. For instance, immunotherapy in the market is the use of immune checkpoint inhibitors. These inhibitors, such as pembrolizumab and nivolumab, block the interaction between cancer cells and immune cells, thereby permitting the immune system to recognize and attack the cancer cells.
Moreover, the rise in the use of immunotherapy in the market can be attributed to its efficacy and favorable safety profile. Unlike traditional treatments such as chemotherapy and radiotherapy, which can have side effects, immunotherapy tends to have fewer negative effects. This makes it a more attractive option for patients, especially those who may not tolerate or respond well to conventional therapies. Therefore, such factors are anticipated to expand the demand for immunotherapy for treating head and neck cancer, which will drive the growth of the immunotherapy segment of the market during the forecast period.
For more insights about the market share of various regions Download PDF Sample
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period.
This region holds a significant position in the market. North America, in recent years, has witnessed substantial growth, due to various factors, such as advancements in medical technology, increasing healthcare infrastructure, and a high prevalence of head and neck cancer cases. The major factors contributing to the growth of the market in North America are the presence of well-established healthcare facilities and a robust pharmaceutical R&D industry.
Furthermore, the radiation and medical oncology specialists at the center collaborate with surgical and imaging experts at the Massachusetts Eye and Ear Infirmary (MEEI) and use advanced imaging technologies, including CT, MRI, and PET/CT, to provide comprehensive care. Therefore, awareness programs on cancer-causing viruses such as human papillomavirus (HPV) and the presence of dedicated head and neck cancer treatment programs are urging the adoption of cancer treatment procedures and driving the growth of the market in the region.
The market addresses a wide spectrum of malignancies, including those affecting the throat and nose, often necessitating surgical treatment or systemic drug therapies. Nonsurgical therapeutics and immunosuppressive treatments play a crucial role in managing malignant tumors, with emerging options like Tipifarnib and Tiragolumab offering promising outcomes. Companies like Merck/Debiopharm are advancing products such as Xevinapant to combat cancer progression. The FDA plays a pivotal role in regulating novel therapies like Tecentriq and Rozlytrek, providing patients with access to innovative treatments. As outpatient visits for cancer care increase, the product pipeline continues to expand, driving advancements in cancer treatment modalities. Nonsurgical therapies for cancer treatment include the farnesyltransferase inhibitor Tipifarnib (Farnesyltransferase Inhibitor), which helps combat immunosuppression, as well as other innovative drugs like Tiragolumab (anti-TIGIT), Tecentriq (atezolizumab), and Rozlytrek (entrectinib). Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The increasing incidence of head and neck cancers is notably driving the market growth. Head and neck cancers include cancers in the oral cavity, pharynx (nasopharynx, oropharynx, and hypopharynx), larynx, paranasal sinuses and nasal cavity, and salivary glands. Generally, head and neck cancers are attributed to squamous cell carcinoma (SCC), which is mostly diagnosed late with a poor prognosis and is particularly prevalent among men who have a significant history of alcohol consumption and/or tobacco use. SCCHN develops around the mucosal linings of the upper aerodigestive tract.
SCCHN is the sixth-leading cancer in terms of incidence, with about half a million new cases diagnosed every year globally. Head and neck cancers accounted for about 4% of all cancers in the US, and also estimated 562,328 people worldwide were diagnosed with head and neck cancer in 2020. In the US, according to the Centers for Disease Control and Prevention (CDC), the human papillomavirus (HPV) is responsible for about 70% of all oropharyngeal cancer. The number of new cases of HPV-associated oropharyngeal cancers diagnosed every year in men is about 15,500, while that in women is about 3,500. According to the National Health Service (NHS) in the UK, about 12,000 new cases of head and neck cancer are diagnosed annually in the UK. Furthermore, about 8,300 people are diagnosed with mouth cancer in the UK every year, which contributes to 1 out of every 50 cancers that are diagnosed. Therefore, such factors are expected to drive the growth of the market during the forecast period.
The growing trend of oncology-related medical tourism is an emerging trend shaping market growth. Current advancements in medical technology allow the reduction or complete cure of cancer. The latest medical treatment is not always available or accessible to everyone owing to several reasons, including its affordability. Oncology treatment can be very costly. In the US, some diagnostic procedures and treatment cycles can be very costly, but the same procedure may be less expensive in other countries, such as India. People prefer to travel to foreign destinations that deliver cost-effective and high-quality healthcare treatment and care. The typical types of cancer treatments for which patients travel abroad include radiation therapy, medical/surgical oncology, chemotherapy, targeted/proton therapy, head and neck cancer therapeutics, and immunotherapy.
Additionally, the most prevalent medical tourism destinations for cancer treatment are Germany, Spain, France, India, and Israel. Germany offers superior technology-based treatments, while France has the highest success rate in Europe, and Spain focuses on providing alternative treatment options for oncology. On the other hand, developing countries such as India provides up-to-date oncology diagnostics and treatment methods at cost-effective rates, while Israel is a favored option for its highly advanced facilities. Consequently, the growing trend of oncology-related medical tourism is likely to positively impact the demand for diagnostics and treatment in the market during the forecast period.
Lack of access to quality healthcare in underdeveloped regions is a significant challenge hindering market growth. Low- and middle-income countries bear most of the disease burden but contribute a meager share to overall global healthcare expenditure. The rapid population growth rate in many developing countries necessitates advancement in the quality of both healthcare and related infrastructure. Nevertheless, various factors are responsible for the restricted access to healthcare in the least developing countries, including the lack of knowledge and resources, shortage of trained medical practitioners, and the high cost of head and neck cancer drugs. In many underdeveloped and developing regions, the lack of knowledge and awareness is compounded by the lack of proper healthcare infrastructure.
Further, the dearth of trained medical practitioners is widespread in underdeveloped regions. Consequently, the overall healthcare system in most of these countries requires numerous reforms to meet the rising demand for quality healthcare. Despite foreign investments from global institutions, such as The World Bank Group, WHO, and the Bill and Melinda Gates Foundation, along with several other non-profit organizations and local governments, the disparities in healthcare systems continue to exist in poorer, underdeveloped, and developing countries. Thus, the lack of awareness and restricted access to healthcare hinder the growth of the market during the forecast period.
The market forecast report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market forecasting and growth strategies.
Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Head and Neck Cancer Diagnostic Methods Market: Head and Neck Cancer Diagnostic Methods Market by Diagnostic Methods, End-user and Geography - Forecast and Analysis
India Oncology Market: India Oncology Market by Type and End-user - Forecast and Analysis
Laryngeal Cancer Therapeutics Market: Laryngeal Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast
The market is advancing with innovative approaches like pipeline drugs such as afatinib and ipilimumab. Non-surgical procedures and combination therapies are gaining prominence, alongside diagnostic tools for precise interventions. The biopharmaceutical industry is spearheading breakthroughs, with online pharmacies expanding access. PD-L1 inhibitors like Opdivo, Keytruda, and Dostarlimab are transforming treatment paradigms, especially for head and neck squamous cell carcinoma (HNSCC). Retail and specialty pharmacies including Humana Specialty Pharmacy and CVS Specialty, play pivotal roles in the prescription of immunotherapy drugs. Research and Development activities by institutions like the Cancer Research Institute drive innovation, targeting multiple HNCs with precision and efficacy.
Further, tobacco consumption and alcohol are significant risk factors for head and neck cancer (HNC), often associated with Epstein-Barr virus (EBV) and human papillomavirus (HPV) infections. Treatment options encompass diverse drug therapies such as capecitabine, cetuximab, and paclitaxel, alongside surgical interventions. Retail pharmacies and online platforms serve as vital sales channels for these medications. Emerging therapies like Merck/Debiopharm's Xevinapant and Tiragolumab are undergoing Phase II clinical trials, targeting metastatic or recurrent HNC. Immunotherapies like pembrolizumab (Keytruda) and nivolumab (Opdivo) show promise in treating squamous head and neck cancer (HNSCC), aiming to improve patient outcomes and quality of life by mitigating hair loss and speech difficulties.
Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.64% |
Market Growth 2024-2028 |
USD 7.12 billion |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
11.73 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, China, Germany, UK, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Amgen Inc., AstraZeneca Plc, Ayala Pharmaceuticals Inc., Bristol Myers Squibb Co., Debiopharm International SA, Eli Lilly and Co., Incyte Corp., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.